Phase 1 Results of Exicorilant + Enzalutamide in Patients with Castration-Resistant Prostate Cancer
Linch et al • 2022 • European Society for Medical Oncology (ESMO) Congress 2022
© 2024 Corcept Therapeutics, Incorporated
About jeremiah@devisedesigns.com
This author has not written his bio yet.
But we are proud to say that jeremiah@devisedesigns.com contributed 143 entries already.
Entries by jeremiah@devisedesigns.com
Relacorilant + Nab-paclitaxel in Patients with Recurrent, Platinum-resistant Ovarian Cancer: Phase 2 Subgroup Analysis Mirroring the Patient Population of an Upcoming Phase 3 Study
Colombo et al • 2022 • European Society for Medical Oncology (ESMO) Congress 2022
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors
Munster et al • 2022 • Clin Cancer Res OF1–OF11
Impact of mifepristone on liver function and liver steatosis in patients with Cushing Syndrome
East et al • 2022 • ENDO 2022 Annual Meeting
Overall survival data from a 3-arm, randomized, open-label phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer
Colombo et al • 2022 • American Society of Clinical Oncology Annual Meeting
A study of relacorilant in combination with nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
Borazanci et al • 2022 • American Society of Clinical Oncology Annual Meeting
DAZALS: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis
Mann et al • 2022 • European Network to Cure ALS (ENCALS)
Favorable liver safety profile of the selective glucocorticoid receptor modulator relacorilant in healthy and hepatically impaired adults and in patients with cushing syndrome
Moritis et al • 2022 • European Congress of Endocrinology
Mifepristone Use in Hypercortisolism from an Unknown Source: A Case Study
Brown et al • 2022 • American Association of Clinical Endocrinology (AACE) Annual Meeting